Company intelligence / Profile preview

Beijing Union Medical Products

Beijing*, Beijing, China

Ownership: Private
Development stage: Other

Overview

BUPF has developed several original drugs including the exclusive Class 1 drug bicyclol for hepatitis/liver protection. Bicyclol is approved in China and other countries. Other pipeline assets include meisoindigo for neoplasms and azvudine for viral infections. The company’s manufacturing site is GMP certified by multiple international agencies.

Therapeutic areas: Infectious DiseasesGastroenterologyImmunologyOncology
Modalities: Small molecule drugTabletCapsuleCreamOintmentFreeze-dried powder injection (antitumor drugs)Small volume injection
Industry: Biotech

Beyond the preview

Go deeper on Beijing Union Medical Products.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Beijing Union Medical Products.

Explore the full profile